Diabetes therapeutic inertia
WebOvercoming Therapeutic Inertia Therapeutic inertia is a well-known problem in the management of diabetes. Treatment intensification may be delayed for a prolonged period due to several reasons. Kamlesh Khunti, FMedSci, FRCGP, FRCP, MD, PhD, presented an overview of the scope and impact of therapeutic inertia as well as clinician barriers ... Webthe A1C was ≥ 8% (i.e., encounters with uncontrolled diabetes and possible therapeutic inertia). 5. Use each patient’s medical record to complete the “Act Now –Therapeutic Inertia in Clinical Practice: Self-Assessment” tool. 6. Consider, as you review the cases, that therapeutic inertia is a matter of timely intensification. Timing
Diabetes therapeutic inertia
Did you know?
WebClinical Inertia and 2-Year Glycaemic Trajectories in Patients with Non-Newly Diagnosed Type 2 Diabetes Mellitus in Primary Care: A Retrospective Cohort Study Javascript is currently disabled in your browser. WebMar 30, 2024 · Cook CB, Castro JC, Schmidt RE, et al. Diabetes care in hospitalized noncritically ill patients: More evidence for clinical inertia and negative therapeutic momentum. J Hosp Med 2007;2:203–211 Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure.
WebJul 30, 2024 · Therapeutic inertia in diabetes is a result of several patient-, provider-, and system-level factors. In a meta-analysis, researchers sought to identify interventions that have been used to overcome therapeutic inertia in the setting of type 2 diabetes. Only studies published in peer-reviewed journals between 2004 and 2024 were included in the ... WebMay 3, 2024 · Therapeutic inertia has been shown present in all stages of treatment intensification, from the first oral antihyperglycaemic drug (OAD), all the way to the …
WebApr 12, 2024 · Schernthaner, G. et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc. Diabetol. 19 , 185. WebJun 30, 2024 · Given the complex nature of diabetes clinical and self-management, people with diabetes often face something called clinical or therapeutic inertia. Therapeutic inertia occurs when individuals do not intensify or change their treatment protocols despite not achieving their A1C goal.
WebThat’s what the Overcoming Therapeutic Inertia Initiative aims to determine. The program brings together researchers, health care providers, industry leaders, and others involved …
WebFeb 1, 2024 · Therapeutic inertia is a common occurrence in the care of people with diabetes and impairs the ability of patients with diabetes to attain and maintain glycemic … incentive\\u0027s r2WebNov 11, 2024 · The existence of therapeutic inertia in managing chronic diseases for which treatment algorithms and therapeutic goals are well established, such as diabetes, hypertension, hyperlipidemia ... incentive\\u0027s rWebFeb 1, 2024 · The factors contributing to therapeutic inertia that are related to patients’ medication experiences are numerous and include concerns about side effects and out-of-pocket costs, stigmatization for having diabetes, confusion among clinicians and patients about frequent changes in evidence-based care guidelines, health literacy deficits, and … income discrimination housingWebPrimary Care Diabetes. Volume 12, Issue 1, February 2024, Pages 87-91. Brief report. Therapeutic inertia amongst general practitioners with interest in diabetes. Author links open overlay panel ... income disparity in indiaWebTherapeutic inertia (also known as clinical inertia) is a measurement of the resistance to therapeutic treatment for an existing medical condition. ... It has now become a standard metric for analysing treatment of many common comorbidities such as … incentive\\u0027s r5WebFeb 1, 2024 · Therapeutic inertia can be exacerbated when patients do not seek needed changes to their care regimen. Patient-related factors that may hinder optimal diabetes management include adverse effects of medications, difficulty with regimen complexity, high costs, fear of hypoglycemia, and difficulty adhering to lifestyle modifications ( 19 ). incentive\\u0027s r4WebOct 21, 2024 · Therapeutic inertia is common, affecting as many as 50% of patients with type 2 diabetes, 1 and is driven by a wide range of barriers at the clinician, patient, and … incentive\\u0027s pw